Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canopy Growth Corp T.WEED

Alternate Symbol(s):  T.WEED.DB | CGC

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.


TSX:WEED - Post by User

Bullboard Posts
Post by Balthuson Jun 29, 2017 10:54am
143 Views
Post# 26419093

Medreleaf Fiscal Year 2017 just published, impressive

Medreleaf Fiscal Year 2017 just published, impressiveMedreleaf -Sales of $40.3 million, EBITDA +$13.9 million. Market cap half of Canopy. Opinions?
https://investors.medreleaf.com/press-releases/press-release-details/2017/MedReleaf-Reports-Fourth-Quarter-and-Fiscal-Year-2017-Results/default.aspx


Fiscal Year 2017 Highlights
Sales of $40.3 million, an increase of 109% from the prior year
Adjusted Product Contribution Margin of $30.9 million, an increase of 159% from the prior year
Adjusted EBITDA of positive $13.9 million, an increase of 200% from the prior year
Cash cost per gram produced of $1.73 compared to $3.23 in the prior year
First Canadian Licensed Producer to bring cannabis capsules to market
etc, etc see link for more
https://investors.medreleaf.com/press-releases/press-release-details/2017/MedReleaf-Reports-Fourth-Quarter-and-Fiscal-Year-2017-Results/default.aspx
Bullboard Posts